Lawrence Biegelsen: Okay. Yeah. So I agree with that on the front-end loaded comment. Liam thanks. And then on the LRP, I guess, maybe two-parts. One, if I’m just thinking about the math right the 5% — I think the midpoint for revenue, it’s about 5% organic this year in 2023, if I’m thinking about that right but 6% now for the LRP. So it implies an acceleration in 2024 and 2025 if I’m thinking about that, right. And on the margins, to follow-up on the earlier question, people are going to now look at this operating margin for example, at 26.3 at the midpoint for 2023 and approximately 29% goal in 2025. That’s a pretty big step-up of about 300 basis points. So, basically what gives you the confidence in both of those if I’m thinking about the revenue acceleration in 2024 and 2025 correctly here? And then, on the margins basically 150 basis points a year, in 2024 and 2025. What gives you that confidence? Thanks for taking my questions.
Liam Kelly: Okay. So I’ll cover the LRP, and Tom will cover the margin question. But I know, what Tom’s answer is it’s going to be really focused on inflation Larry, which should be no surprise to anybody given the environment that we’re in. But let me cover the revenue. It’s all constant currency. So what I’m going to talk about is constant currency. So the first year of the LRP will be 5.5%. We’re at the — we’re guiding to the low end of our LRP which is 6%. So you are correct. There is a modest up-tick in revenue as you go from this year 2023 and to 2024 and 2025. And why is that? One of the main reasons for that is the improving macro environment that we expect to see beginning as we go through 2023 and continuing into 2024 and 2025.
The second factor that will help that is the international expansion of some of our high-growth portfolio not just UroLift but also the international expansion of PICCs the international expansion of the intraosseous portfolio the international expansion of the hemostatic products that will bring accelerated growth in the latter half of the LRP. And we feel pretty confident in that. It’s not a managed step-up. We’re going from 5.5% to a 6% CAGR over the horizon of the LRP. And I think the other comment that I will make, that nobody has picked up on so far in their questioning is, durable core was 4% to 5%. While we’ve been micro-focused on one element of Teleflex the durable core has been improving all this time. And now the durable core for the LRP is now 5% at the upper end of the original guide of 4% to 5%, through excellent execution by the businesses globally.
And the margins on a high-portion of that durable core are fairly substantive and helpful to Teleflex. And it’s a $14 billion global TAM, for the high-growth and we’re only 5% penetrated. So the opportunities for us to continue to grow into that are significant. But I’ll let Tom address the margin question that you had Larry. And thanks for the questions.
Thomas Powell: Sure, Larry. So the driver of the op margin expansion is really going to come from — largely from the gross margin. And as you break that down, we’re expecting continued margin accretion due to mix and price. Additionally, we have the MSA with Medline which ends at the end of 2023 and that adds close to a full point of margin as a result of that. And then, the third area is that, typically, we have enough productivity in our operations to more than offset inflation. That wasn’t the case in 2022. That’s not the case in 2023. We do expect to see that — some improvement as we go into 2024 and 2025 on inflation. And as a result operations productivity once again becomes accretive to gross margin versus dilutive in 2022 and 2023.
